Focus: Tempus is an AI-driven biotechnology company specializing in drug discovery and medical devices across oncology, gastroenterology, ophthalmology, neurology, and cardiovascular indications. The company operates as a mid-cap biotech with active hiring across 144 open roles and recent validation from major pharma partnerships (AstraZeneca, BioNTech, Merck).
Profile data last refreshed 4h ago · AI intelligence enriched 1mo ago
Hot — 142 jobs added in 30d
Net +72 (142 new, 70 removed). Aggressive expansion phase.
Tempus is a data-first biotech with strong strategic validation but a light clinical pipeline; best suited for AI/RWE-focused professionals comfortable with early-stage uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tempus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tempus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
TEM Stock Jumps As Tempus AI Lands Big Pharma Data Deals - Timothy Sykes
TEM Stock Jumps As Tempus AI Lands Big Pharma Data Deals Timothy Sykes
Pathos Ai Enters Drug Development Collaboration with Bristol Myers Squibb and Tempus Ai - Pharmaceutical Executive
Pathos Ai Enters Drug Development Collaboration with Bristol Myers Squibb and Tempus Ai Pharmaceutical Executive
Pathos AI Expands Beyond Oncology with BMS and Tempus Neuroscience Partnerships - Analytics Insight
Pathos AI Expands Beyond Oncology with BMS and Tempus Neuroscience Partnerships Analytics Insight
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development - Reuters
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development Reuters
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions - Business Wire
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions Business Wire
Tempus AI posts 22% revenue growth, eyes $1.6bn by 2026 with Big Pharma deals and MRD cancer testing expansion - Pluang
Tempus AI posts 22% revenue growth, eyes $1.6bn by 2026 with Big Pharma deals and MRD cancer testing expansion Pluang
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Evaluation of radiomics and radiologic signatures for diagnosis and clinical outcomes in pancreatic adenocarcinoma and pancreatic neuroendocrine: A pilot study.
Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo